Reducing the Abuse of Opioids in Drug Users

Status Terminated

Clinical Trial Summary

The consequences of prescription opioid abuse are serious and the number of deaths from unintended overdose have quadrupled over the last 15+ years. Opioid analgesics remain among the most commonly abused class of substances in the United States. Moreover, patients who take pain medications for legitimate reasons may develop an opioid use disorder (OUD), with as many as 1 in 4 patients becoming dependent on their pain medications. Because of changing access to prescription opioid analgesics due to an increasingly negative prescribing climate and changes in guidelines, patients often turn to heroin, with an estimated 1 in 15 pain patients trying heroin within 10 years. Pain is a symptom that can be severely debilitating and needs to be treated adequately to improve the quality of life. Clinicians, then, are in a proverbial "catch-22" situation whereby treating a patient's chronic pain also exposes them to medications with substantial abuse liability and overdose risk. In this proposal, a method aimed at reducing the abuse potential of prescription opioid medications, without altering their analgesic efficacy, is described. The study team hypothesize that this can be accomplished by administering a fixed-dose-combination of an opioid with an atypical antipsychotic drug, in the same pill or capsule.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03837860
Study type	Interventional
Source	The University of Texas Health Science Center at San Antonio
Contact
Status	Terminated
Phase	Early Phase 1
Start date	April 1, 2019
Completion date	January 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03675386` - Reducing Opioid Use for Chronic Pain Patients Following Surgery	N/A
Completed	`NCT02593474` - Medication-Assisted Treatment for Youth With Substance Use Disorders	Phase 1
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT02294253` - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone	Phase 2/Phase 3
Completed	`NCT01592461` - Starting Treatment With Agonist Replacement Therapies Follow-up Study	N/A
Terminated	`NCT00768482` - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence	Phase 3
Completed	`NCT01741350` - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users	N/A
Terminated	`NCT04121546` - Collaborative Care for Opioid Dependence And Pain Pilot Study	N/A
Withdrawn	`NCT03368794` - Naloxone to TReatment Entry in the Emergency Setting	N/A
Completed	`NCT03447743` - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder	Early Phase 1
Completed	`NCT04464421` - SMART Effectiveness Trial	N/A
Recruiting	`NCT04189523` - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage	N/A
Completed	`NCT03305666` - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures	Phase 4
Recruiting	`NCT04003948` - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification	Phase 2
Not yet recruiting	`NCT03813095` - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction	Phase 2
Terminated	`NCT02935101` - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants	Phase 2
Completed	`NCT01895270` - Improving Buprenorphine Detoxification Outcomes With Isradipine	Phase 1/Phase 2
Completed	`NCT01717963` - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway	Phase 3
Completed	`NCT02324725` - Biomarkers of Injectable Extended Release Naltrexone Treatment	Phase 4
Completed	`NCT01425060` - Improving Effective Contraceptive Use Among Opioid-maintained Women	Phase 1